Central nervous system involvement in multiple myeloma is rare, occurring in only a small fraction of patients, but it is among the most devastating manifestations of the disease. When malignant plasma cells seed the leptomeninges, the delicate layers of tissue enveloping the brain and spinal cord, patients typically experience rapid neurological deterioration. Standard myeloma therapies, including proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies, are designed to act within the bone marrow and bloodstream, and most penetrate the blood-brain barrier poorly, if at all. For decades, this pharmacological frontier has left clinicians with few options beyond intrathecal methotrexate, which can temporarily clear malignant cells from the cerebrospinal fluid but rarely controls the systemic disease driving the relapse.

The patient at the center of the new report presented with high-risk immunoglobulin G kappa multiple myeloma harboring two ominous cytogenetic abnormalities: a deletion of the short arm of chromosome 17, which implicates the TP53 tumor suppressor gene, and a deletion of chromosome 13q. Both alterations are associated with aggressive disease biology and shortened survival. By the time of her CNS relapse, she had undergone two autologous stem cell transplants and had become refractory to all three major drug classes used against myeloma, a status known as triple-class refractory disease. Her malignant plasma cells had also escaped the bone marrow, forming extramedullary masses, a further signal of highly aggressive, treatment-resistant biology.

The clinical picture at CNS relapse was unambiguous. Cerebrospinal fluid cytology revealed abundant atypical and binucleated plasma cells, the morphological hallmark of malignant plasma cell infiltration of the meninges. Magnetic resonance imaging of the brain and spine showed diffuse leptomeningeal enhancement, indicating widespread disease along the neural axis. In most published series, patients with leptomeningeal myeloma at this stage of treatment refractoriness survive only a few months, and many die within weeks of diagnosis.

Rather than pursuing conventional salvage chemotherapy, the treating physicians, Sinan Mersin of Mersin University Faculty of Medicine and Ömür Gökmen Sevindik of İstanbul Demiroğlu Science University, Florence Nightingale Hospital, elected to combine a systemic immunotherapy with a CNS-directed strategy. The systemic component was elranatamab, a bispecific antibody that binds B-cell maturation antigen, or BCMA, a protein expressed almost universally on malignant plasma cells, on one arm and CD3, a component of the T-cell receptor complex, on the other. By physically linking a patient’s own T lymphocytes to myeloma cells, elranatamab converts the immune system into a targeted killing machine, bypassing the need for the antigen-presentation machinery that many tumors evade.

Because bispecific antibodies can trigger an uncontrolled inflammatory response as T cells activate and release cytokines, the drug was introduced using a standard step-up dosing schedule. Lower initial doses prime the immune system and reduce the risk of cytokine release syndrome, the potentially life-threatening inflammatory storm characterized by fever, hypotension, and organ dysfunction. Intrathecal therapy, consisting of methotrexate delivered directly into the cerebrospinal fluid together with dexamethasone, was administered concurrently to attack the malignant plasma cells already circulating within the CNS compartment. The logic of the combination is compelling: the intrathecal drugs provide immediate local control while the bispecific antibody, once fully dosed, generates a sustained systemic immune assault against BCMA-expressing clones wherever they reside.

The response was both rapid and complete. Within two months of starting therapy, follow-up MRI demonstrated complete resolution of the leptomeningeal enhancement, and cerebrospinal fluid examination showed no cells at all, indicating that malignant plasma cells had been eradicated from the CNS. Crucially, the systemic disease responded in parallel. Evaluation according to the criteria of the International Myeloma Working Group confirmed a complete response, with normalization of serum immunofixation, protein electrophoresis, and free light chain measurements, the laboratory pillars used to track myeloma burden. The monoclonal protein that had defined her disease could no longer be detected.

Equally notable was the tolerability of the regimen. The patient experienced no cytokine release syndrome and no neurotoxicity, the two toxicities that most commonly complicate bispecific antibody therapy and that are of particular concern when the CNS is already compromised. The step-up dosing schedule, combined with careful monitoring, appears to have allowed the immune activation to proceed without crossing the threshold into clinical toxicity. This safety profile is especially relevant for patients with CNS disease, in whom fever or neurological changes can be difficult to distinguish from disease progression and can delay potentially curative treatment.

Perhaps the most striking finding is the durability of the remission. At the time of the report, eighteen months after initiating elranatamab, the patient remains in ongoing complete remission, including sustained clearance of the CNS. For a disease state in which median survival is typically measured in single-digit months, this duration of response represents an extraordinary departure from the expected natural history. The authors suggest that BCMA-targeted bispecific antibodies, when combined with CNS-directed therapy, may be capable of inducing deep and durable remissions even in patients whose myeloma has breached the blood-brain barrier after extensive prior treatment.

The case also carries broader implications for the evolving landscape of myeloma immunotherapy. Bispecific antibodies have transformed the treatment of relapsed and refractory multiple myeloma in recent years, offering off-the-shelf alternatives to chimeric antigen receptor T-cell therapy, which requires individualized manufacturing and is logistically demanding. Elranatamab received accelerated approval for relapsed or refractory disease based on promising results in clinical trials, and other BCMA-targeted bispecifics have shown similar efficacy. Whether these agents penetrate the CNS in meaningful concentrations remains an open question, but this case demonstrates that, at minimum, systemic BCMA redirection combined with intrathecal chemotherapy can achieve CNS clearance. Some evidence from CAR-T studies suggests that BCMA-directed cellular therapies can themselves cross the blood-brain barrier and exert intracranial activity, and it is plausible that activated T cells recruited by bispecific antibodies behave similarly.

The authors emphasize that their report describes a single patient and therefore cannot establish standard of care. Case reports in rare disease states serve as hypothesis generators, and the appropriate next step, they argue, is formal investigation of bispecific antibodies in CNS-involved myeloma, ideally through prospective clinical trials that incorporate CNS response endpoints and standardized intrathecal regimens. The subcutaneous administration route used for elranatamab, which allows outpatient management after the step-up phase, could make such an approach practical compared with hospital-based CAR-T infusions.

For patients and families facing a diagnosis of CNS-involved myeloma, the message from this case is one of cautious hope. A complication long regarded as a terminal event may become a tractable therapeutic target as immunotherapies mature and as clinicians learn to pair systemic immune redirection with direct CNS drug delivery. The eighteen-month remission documented in this Turkish case is a single data point, but it is a data point that challenges decades of therapeutic nihilism and points toward a future in which even the blood-brain barrier no longer offers sanctuary to malignant plasma cells.

Leptomeningeal disease is characterized by the infiltration of malignant cells into the meninges—the thin membranes enveloping the brain and spinal cord. This infiltration disrupts normal neurological function and has historically been associated with dismal prognoses, as there are limited effective treatment strategies and few prospective clinical trials addressing this niche yet critically important patient population. Conventional therapies have yielded minimal impact on survival, necessitating innovative approaches to tackle the rapid progression and immense clinical burden of LMD.

The Moffitt study enrolled 15 patients with leptomeningeal disease originating from diverse primary solid tumors such as breast, lung, ovarian, and pancreatic cancers. Each participant underwent a treatment regimen involving avelumab administered before, during, and after whole brain radiotherapy. Avelumab, a programmed death-ligand 1 (PD-L1) inhibitor, is designed to reinvigorate the immune system’s ability to recognize and eradicate tumor cells by preventing cancer’s immune evasion tactics. Coupled with radiotherapy, which induces tumor cell death and potentially enhances immune visibility of the cancer, this combination explores synergistic mechanisms to drive antitumor immunity within the central nervous system.

Survival outcomes were notably improved compared to historical data, with 67% of patients surviving a minimum of three months post-treatment, and several exceeding one year of survival. This marks a significant shift from previous expectations, where median survival after LMD diagnosis frequently spans only several weeks. These findings underscore the potential of this combinatorial immunotherapeutic strategy to meaningfully extend life expectancy and improve quality of life in a group of patients who have long faced grim prognoses.

Importantly, the safety profile of the combined treatment was manageable, with adverse effects being generally mild to moderate and no fatalities attributed to the therapy. This is crucial in the context of central nervous system involvement, where therapeutic interventions must balance efficacy with the risk of neurotoxicity and other serious complications. The tolerability observed in this trial supports the feasibility of escalating this treatment approach to larger patient cohorts in subsequent trials.

Beyond clinical outcomes, the researchers conducted in-depth molecular analyses of cerebrospinal fluid (CSF) samples collected before and after treatment. These investigations revealed a pronounced immune activation characterized by a reduction of regulatory T cells—a subset that typically suppresses immune response and facilitates tumor immune escape. Moreover, alterations were detected in immune checkpoint activity within CD8+ cytotoxic T cells and macrophages, indicating enhanced immune surveillance and effector function following treatment. These immune modulations provide a mechanistic underpinning for the observed clinical benefits and offer potential biomarkers for treatment response.

Dr. Yolanda Piña, the lead investigator and neuro-oncologist at Moffitt, emphasized the significance of these translational findings, stating that the data not only demonstrate safety and preliminary efficacy but also illuminate how immunotherapy and radiation may synergistically reshape the immune landscape within the central nervous system. This understanding paves the way for rational design of future trials and therapeutic combinations that could further improve outcomes for patients battling leptomeningeal disease.

Senior author Dr. Peter Forsyth, chair of Moffitt’s Neuro-Oncology Department, highlighted the importance of targeting newly identified immune checkpoints such as LAG3, which may contribute to resistance mechanisms. By uncovering these pathways through CSF analysis, the study provides a roadmap for next-generation immunotherapies that could overcome compensatory immune suppression and potentiate durable tumor control.

While the study’s modest sample size and phase 1B design primarily focused on assessing safety, the encouraging survival data and detailed immune profiling collectively justify advancing to a phase 2 clinical trial. Such a trial would enable more robust evaluation of efficacy endpoints, while continuing to elucidate the complex interplay between radiotherapy, immunotherapy, and the neuroimmune microenvironment.

This research represents a milestone in neuro-oncology, expanding the therapeutic armamentarium for leptomeningeal disease—a condition desperately lacking effective treatment options. By harnessing the power of the immune system in tandem with radiation, Moffitt investigators have opened a promising new frontier that may ultimately transform the clinical management of this aggressive complication across multiple solid tumor types.

The study was supported by Pfizer and conducted under a collaborative alliance between the health care business of Merck KGaA and Pfizer. Additional funding was provided by the National Cancer Institute and the Florida Department of Health Bankhead-Coley Program. These partnerships underscore the critical role of multidisciplinary cooperation in advancing cancer therapeutics from bench to bedside.

Moffitt Cancer Center, located in Tampa, Florida, is one of only 57 National Cancer Institute-designated Comprehensive Cancer Centers in the United States. This prestigious designation recognizes Moffitt’s commitment to scientific excellence, multidisciplinary research, and patient-centered care. The center’s dedication to innovation continues to drive forward progress in cancer prevention, diagnosis, and treatment.

In summary, this pioneering trial not only signals a new hope for patients with leptomeningeal disease but also exemplifies how integrating immunotherapy with traditional modalities such as radiotherapy can overcome previously insurmountable barriers imposed by the immune-privileged environment of the central nervous system. The implications extend beyond LMD, potentially impacting therapeutic strategies in diverse neuro-oncological diseases.

Subject of Research: People
Article Title: Phase IB Study of Avelumab and Whole Brain Radiotherapy (WBRT) in Patients with Leptomeningeal Disease (LMD) from Solid Tumors: Results and Molecular Analyses
News Publication Date: Sept. 30, 2025
Web References:
– https://www.moffitt.org/cancers/brain-tumor/leptomeningeal-disease/
– https://academic.oup.com/neuro-oncology/advance-article/doi/10.1093/neuonc/noaf183/8245008
– http://dx.doi.org/10.1093/neuonc/noaf183

References:
– Neuro-Oncology Journal, 28-Aug-2025, DOI: 10.1093/neuonc/noaf183

Keywords: Immunotherapy, Leptomeningeal Disease, Avelumab, Whole Brain Radiotherapy, Neuro-Oncology, Clinical Trial, Immune Checkpoints, CSF Immune Profiling, PD-L1 Inhibitor, Translational Oncology